secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2026-11-05T22:13:17+00:00
Accession:  0001104659-26-123446
Event type: m_and_a
Sentiment:  positive
Materiality: 0.87
Item codes: 1.01, 8.01, 2.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

ANI to buy Egetis for ~$560M cash offer at 27% premium; EMCITATE peak sales seen above $300M
--------------------------------------------------------------------------------

- SEK 11.25 per share cash offer values Egetis at ~SEK 5.6B ($559.9M), a 27% premium to the 60-day VWAP; enterprise value ~$434M after Egetis' $190M priority review voucher sale.
- Egetis board unanimously recommends; holders of ~42.2% of outstanding shares signed irrevocables; closing needs 90% tendered plus regulatory/FDI clearances, acceptance period ~Nov 20-Dec 18, 2026.
- EMCITATE (tiratricol) is the first and only approved MCT8 deficiency treatment - EU approval Feb 12, 2025, FDA Sept 28, 2026 - with >$300M peak sales potential and protection into mid-2045.
- $676M 364-day senior bridge from JPMorgan (ABR+1.75%, adjusted SOFR+2.75%) funds the offer and refinances ANI's existing term loans and Egetis debt; initially unsecured, then guaranteed/secured.
- ANI reports 3Q 2026 results the same morning ahead of an 8:00 a.m. ET call; Jefferies is ANI's sole financial advisor, Centerview advises Egetis, with Ropes & Gray and Mannheimer Swartling as counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000110465926123446/0001104659-26-123446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000110465926123446/tm2628706d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-123446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer